Combination Therapy of Navitoclax with Chemotherapeutic Agents in Solid Tumors and Blood Cancer: A Review of Current Evidence

Combination therapy emerges as a fundamental scheme in cancer. Many targeted therapeutic agents are developed to be used with chemotherapy or radiation therapy to enhance drug efficacy and reduce toxicity effects. ABT-263, known as navitoclax, mimics the BH3-only proteins of the BCL-2 family and has...

Descripción completa

Detalles Bibliográficos
Autores principales: Nor Hisam, Nur Syahidah, Ugusman, Azizah, Rajab, Nor Fadilah, Ahmad, Mohd Faizal, Fenech, Michael, Liew, Sze Ling, Mohamad Anuar, Nur Najmi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8468743/
https://www.ncbi.nlm.nih.gov/pubmed/34575429
http://dx.doi.org/10.3390/pharmaceutics13091353

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8468743/
https://www.ncbi.nlm.nih.gov/pubmed/34575429
http://dx.doi.org/10.3390/pharmaceutics13091353

Ejemplares similares